Molecular markers for melanoma prognosis and their applications

Through the expression scores of the four genes, TMEM67, TMEM107, SLC9A3R1, PKHD1L1 and DZIP1, the problems of melanoma prognosis diagnosis and immunotherapy sensitivity prediction are solved, and personalized treatment plans are provided, which improves the effect and survival of melanoma treatment. predict.

CN116179703BActive Publication Date: 2024-11-15AMOY DIAGNOSTICS CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310124109.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-02-16
Publication Date
2024-11-15
Estimated Expiration
2043-02-16

AI Technical Summary

Technical Problem

The lack of effective biomarkers for the prognostic diagnosis and treatment of melanoma, especially insufficient markers associated with cilia, makes it difficult to accurately predict the risk of recurrence and immunotherapy sensitivity in patients.

Method used

Using the four genes, TMEM67, TMEM107, SLC9A3R1, PKHD1L1 and DZIP1, as molecular markers, risk scores are performed through their expression levels, and kits and detection systems are provided for the applicability of melanoma prognostic diagnosis and immunotherapy to help develop personalized Treatment plan.

Benefits of technology

Accurate assessment of prognostic risk in melanoma patients and prediction of immunotherapy sensitivity are achieved, new diagnostic and treatment options are provided, and the effectiveness of clinical treatment and the accuracy of patient survival prediction are improved.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004082361180000131
    Figure BDA0004082361180000131
  • Figure BDA0004082361180000141
    Figure BDA0004082361180000141
  • Figure BDA0004082361180000151
    Figure BDA0004082361180000151
Patent Text Reader

Abstract

The present invention provides a biomarker related to melanoma prognosis and its application. The biomarker can be used for diagnosis and / or prediction of melanoma prognosis risk. The present invention also provides a kit suitable for diagnosis and / or prediction of melanoma prognosis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine, and more specifically, relates to molecular markers for melanoma prognosis and applications thereof. Background Art

[0002] Melanoma is a skin cancer that develops from pigment cells and has been extensively studied, especially in terms of the immune response of the tumor, and has been used as a model for the development of immunotherapy. This is partly due to the high mutation burden observed in melanoma, which has increased immunogenicity and immune cell infiltration compared to other types of cancer. Although immune checkpoint blockade has achieved great success in melanoma, most patients do not benefit from long-term remission, and a considerable proportion of patients suffer from long-term immune-related side effects. Therefore, a deep understanding of the biological mechanisms of tumor occurrence is critical for the development of new melanoma therapies. As the tumor develops, it accumulates more and more genetic and epigenetic changes. Although these epigenetic factors cannot directly affect the gene sequence, they can regulate the transcription efficiency of specific genes in the cell, help improve the immunogenicity of tumor cells and the infiltration of immune cells, and play an important role in the formation and spread of melanoma.

[0003] Most cells in the human body have cilia, which are organelles protruding from the surface of vertebrate cells and are the connection points of multiple signaling pathways, especially the sonic hedgehog (SHH) and wingless (WNT) signaling pathways. In an article published on November 1, 2021 in NC, the authors used a zebrafish melanoma model to find that such a unique "interface" where tumors contact adjacent tissues is composed of special tumor cells and microenvironment cells. These cells upregulate a set of common ciliary genes, and ciliary proteins are enriched only where tumors contact the microenvironment. The expression of ciliary genes is regulated by ETS family transcription factors, which usually play a role in inhibiting ciliary genes outside the interface. Other studies have shown that a large number of solid cancers show a loss of primary cilia consistent with reduced ciliary gene expression. However, the mechanism by which cancer cells lose cilia and the significance of ciliary loss to tumorigenesis remain a mystery. In melanoma, benign moles have cilia, while most malignant melanomas do not have primary cilia. In July 2018, a research report published in Cancer Cell showed that these excellent sensory tentacles on the cell surface may play a key role in the occurrence of melanoma. The loss of cilia enhances tumor-promoting WNT / β-catenin signaling. When cilia are inhibited from growing and developing in benign pigment cells, the cells will degenerate and progress into malignant forms of melanoma. Because there is a very close connection between cilia and cancer occurrence, scientists have found that blocking the growth of cilia in drug-resistant cancer cell lines may restore the sensitivity of cancer cells to therapy.

[0004] Therefore, it is necessary to find prognostic and predictive biomarkers based on the expression values ​​of cilia-related genes that can identify people with high risk of recurrence or progression, and then study whether therapies targeting cilia structure can be used as cancer treatment. Summary of the invention

[0005] The object of the present invention is to provide a biomarker related to melanoma prognosis and its application. The biomarker includes TMEM67, TMEM107, SLC9A3R1, PKHD1L1, DZIP1, which can be used for diagnosis and / or prediction of melanoma prognosis risk. The present invention also provides a kit suitable for diagnosis and / or prediction of melanoma prognosis.

[0006] In a first aspect of the present invention, a molecular marker is provided for use in preparing a detection system for detecting or prognosing melanoma, or prognosing the suitability of immunotherapy; the molecular marker is selected from TMEM67, TMEM107, SLC9A3R1, PKHD1L1, DZIP1 or a combination thereof.

[0007] In one or more embodiments, the detection or prognosis comprises: based on the expression of molecular markers:

[0008] (a) analyzing the sensitivity of melanoma patients to immunotherapy; preferably, further comprising: formulating a treatment / medication regimen; preferably, the immunotherapy is immune checkpoint inhibitor therapy; preferably, the immunotherapy is anti-PD-1 / anti-CTLA-4 immunotherapy;

[0009] (b) to analyze major pathological response and / or survival of patients with melanoma; or

[0010] (c) performing a risk analysis or scoring for the development of melanoma in a melanoma patient.

[0011] In one or more embodiments, the molecular marker is a gene associated with melanoma.

[0012] In one or more embodiments, the melanoma-associated gene is a gene associated with cilia growth and / or cilia structure.

[0013] In one or more embodiments, the immunotherapy comprises: anti-PD-1 / anti-CTLA-4 immune checkpoint inhibitor therapy.

[0014] In one or more embodiments, the expression of the gene includes expression at the DNA (gDNA or cDNA) level and expression at the transcription level.

[0015] In one or more embodiments, the molecular markers include transcripts, gDNA, cDNA, DNA / RNA hybrids, or fragments thereof at the gene level of TMEM67, TMEM107, SLC9A3R1, PKHD1L1 or DZIP1; the fragments are specific and sufficient to distinguish the TMEM67, TMEM107, SLC9A3R1, PKHD1L1 or DZIP1 gene from other molecules.

[0016] In one or more embodiments, the molecular markers include TMEM67 protein, TMEM107 protein, SLC9A3R1 protein, PKHD1L1 protein, DZIP1 protein, or fragments thereof at the protein level; the fragments are specific and sufficient to distinguish TMEM67 protein, TMEM107 protein, SLC9A3R1 protein, PKHD1L1 protein or DZIP1 protein from other molecules.

[0017] In one or more embodiments, the immune checkpoint inhibitor comprises an anti-PD-1 antibody.

[0018] In one or more embodiments, the immune checkpoint inhibitor comprises an anti-CTLA-4 antibody.

[0019] In one or more embodiments, the detection system includes (but is not limited to): a detection reagent, a kit or a detection device; preferably, the detection reagent includes (but is not limited to): a PCR detection reagent, a sequencing reagent; more preferably, the detection reagent includes: a primer for specifically amplifying the molecular marker gene, a probe for specifically identifying the molecular marker gene; preferably, the detection reagent is included in the kit; preferably, the detection device includes (but is not limited to): a gene sequencing instrument, a chip, a probe set (module), a primer probe set (module) or an electrophoresis device.

[0020] In one or more embodiments, the gene combination includes: SLC9A3R1 and DZIP1, and a gene selected from TMEM67, TMEM107 or PKHD1L1.

[0021] In one or more embodiments, the gene combination is selected from:

[0022] TMEM67, TMEM107, SLC9A3R1, PKHD1L1, and DZIP1;

[0023] TMEM67, TMEM107, SLC9A3R1, and DZIP1; or

[0024] SLC9A3R1, PKHD1L1, and DZIP1.

[0025] In one or more embodiments, the detection method comprises:

[0026] (a) For the sample to be tested, the expression of TMEM67, TMEM107, SLC9A3R1, PKHD1L1 and / or DZIP1 is measured, and risk analysis or scoring is performed using any of the following risk scoring formulas:

[0027] Risk score 1 = (Coef TMEM67 ×TMEM67 expression)+(Coef TMEM107 ×TMEM107 expression)+(Coef SLC9A3R1 ×SLC9A3R1 expression)+(Coef PKHD1L1 ×PKHD1L1 expression)+(Coef DZIP1 ×DZIP1 expression);

[0028] Risk score 2 = (Coef TMEM67 ×TMEM67 expression)+(Coef TMEM107 ×TMEM107 expression)+(Coef SLC9A3R1×SLC9A3R1 expression)+(Coef DZIP1 ×DZIP1 expression);

[0029] Risk score 3 = (Coef SLC9A3R1 ×SLC9A3R1 expression)+(Coef PKHD1L1 ×PKHD1L1 expression)+(Coef DZIP1 ×DZIP1 expression);

[0030] (b) Determine the threshold (cut-off value);

[0031] (c) Compare the result of (a) with the threshold of (b) to obtain the detection result.

[0032] In one or more embodiments, in (a), the risk coefficient of the gene is:

[0033] Coef TMEM67 : 0-1, preferably 0.01±0.005 (more preferably 0.01±0.002);

[0034] Coef TMEM107 : 0-1, preferably 0.031±0.015 (more preferably 0.031±0.01);

[0035] Coef SLC9A3R1 : -1 to 0, preferably -0.024 ± 0.01 (more preferably -0.024 ± 0.005);

[0036] Coef PKHD1L1 : -1 to 0, preferably -0.172 ± 0.07 (more preferably -0.172 ± 0.03);

[0037] Coef DZIP1 : 0~1, preferably 0.012±0.008 (more preferably -0.024±0.004).

[0038] In one or more embodiments, in the 0 to 1 or -1 to 0, the Coef includes 0, 1 or -1.

[0039] In one or more embodiments, in (c), if the score value is ≥ the threshold, the evaluation is: poor prognosis, high risk of recurrence, or insensitive to immune checkpoint inhibitor treatment; if the score value is < the threshold, the evaluation is: good prognosis, low risk of recurrence, or sensitive to immune checkpoint inhibitor treatment; preferably, the threshold of the risk score 1 is 0.093; the threshold of the risk score 2 is 0; the threshold of the risk score 3 is 0.

[0040] In the second aspect of the present invention, a kit or detection device for predicting the prognosis of melanoma or the suitability of immunotherapy is provided, characterized in that it includes detection reagents for predicting the prognosis of melanoma or the suitability of immunotherapy, including: detection reagents for molecular markers, wherein the molecular markers are selected from TMEM67, TMEM107, SLC9A3R1, PKHD1L1, DZIP1 or a combination thereof.

[0041] In one or more embodiments, the detection reagents include (but are not limited to): PCR detection reagents, sequencing reagents; more preferably, the detection reagents include: primers that specifically amplify the molecular marker gene, and probes that specifically recognize the molecular marker gene.

[0042] In one or more embodiments, the detection device also includes (but is not limited to): a gene sequencing instrument, a chip, a probe set (module), a primer probe set (module) or an electrophoresis device.

[0043] In one or more embodiments, the molecular marker is a gene associated with melanoma.

[0044] In one or more embodiments, the melanoma-associated gene is a gene associated with cilia growth and / or cilia structure.

[0045] In a third aspect of the present invention, a system for predicting the prognosis of melanoma or the suitability of immunotherapy is provided, comprising a detection unit and a data analysis unit;

[0046] The detection unit comprises: a detection reagent for determining the expression level of a molecular marker, or a kit or a detection device containing the detection reagent; the molecular marker is selected from TMEM67, TMEM107, SLC9A3R1, PKHD1L1, DZIP1 or a combination thereof;

[0047] The data analysis unit includes: a processing unit for analyzing and processing the detection result of the detection unit to obtain a melanoma prognosis or immunotherapy suitability result.

[0048] In one or more embodiments, the molecular marker is a gene associated with melanoma.

[0049] In one or more embodiments, the melanoma-associated gene is a gene associated with cilia growth and / or cilia structure.

[0050] In one or more embodiments, the gene combination includes: SLC9A3R1 and DZIP1, and a gene selected from TMEM67, TMEM107 or PKHD1L1.

[0051] In one or more embodiments, the test result includes: a diagnosis result or a risk assessment / scoring (eg, grading) result.

[0052] In one or more embodiments, the kit further includes instructions for use, describing the following detection methods:

[0053] (a) For the sample to be tested, the expression of TMEM67, TMEM107, SLC9A3R1, PKHD1L1 and / or DZIP1 is measured, and risk analysis or scoring is performed using any of the following risk scoring formulas:

[0054] Risk score 1 = (Coef TMEM67 ×TMEM67 expression)+(Coef TMEM107 ×TMEM107 expression)+(Coef SLC9A3R1 ×SLC9A3R1 expression)+(Coef PKHD1L1 ×PKHD1L1 expression)+(Coef DZIP1 ×DZIP1 expression);

[0055] Risk score 2 = (Coef TMEM67 ×TMEM67 expression)+(Coef TMEM107 ×TMEM107 expression)+(Coef SLC9A3R1 ×SLC9A3R1 expression)+(Coef DZIP1 ×DZIP1 expression);

[0056] Risk score 3 = (Coef SLC9A3R1 ×SLC9A3R1 expression)+(Coef PKHD1L1 ×PKHD1L1 expression)+(Coef DZIP1 ×DZIP1 expression);

[0057] (b) Determine the threshold (cut-off value);

[0058] (c) Compare the result of (a) with the threshold of (b) to obtain the detection result.

[0059] In one or more embodiments, the data analysis unit includes or integrates the "risk scoring formula" and / or the "threshold value".

[0060] In the fourth aspect of the present invention, a method for predicting the prognosis of melanoma or the suitability of immunotherapy is provided, characterized in that the method comprises: using a detection system for specifically detecting molecular markers to detect molecular markers; the molecular markers are selected from TMEM67, TMEM107, SLC9A3R1, PKHD1L1, DZIP1 or a combination thereof; the detection system comprises a detection reagent, a kit or a detection device.

[0061] In one or more embodiments, the molecular marker is a gene associated with melanoma.

[0062] In one or more embodiments, the melanoma-associated gene is a gene associated with cilia growth and / or cilia structure.

[0063] In one or more embodiments, the gene combination includes: SLC9A3R1 and DZIP1, and a gene selected from TMEM67, TMEM107 or PKHD1L1.

[0064] In one or more embodiments, the method includes: based on the expression of molecular markers; (a) analyzing the sensitivity of melanoma patients to immunotherapy; preferably also including: formulating a treatment / medication plan; preferably, the immunotherapy is anti-PD-1 / anti-CTLA-4 immune checkpoint inhibitor therapy; (b) analyzing the major pathological remission and / or survival of melanoma patients; or, (c) performing risk analysis or scoring for melanoma development in melanoma patients.

[0065] In one or more embodiments, the method comprises:

[0066] (a) For the sample to be tested, the expression of TMEM67, TMEM107, SLC9A3R1, PKHD1L1 and / or DZIP1 is measured, and risk analysis or scoring is performed using a risk scoring formula selected from the following:

[0067] Risk score 1 = (Coef TMEM67 ×TMEM67 expression)+(Coef TMEM107 ×TMEM107 expression)+(Coef SLC9A3R1 ×SLC9A3R1 expression)+(Coef PKHD1L1 ×PKHD1L1 expression)+(Coef DZIP1 ×DZIP1 expression);

[0068] Risk score 2 = (Coef TMEM67 ×TMEM67 expression)+(Coef TMEM107 ×TMEM107 expression)+(Coef SLC9A3R1×SLC9A3R1 expression)+(Coef DZIP1 ×DZIP1 expression);

[0069] Risk score 3 = (Coef SLC9A3R1 ×SLC9A3R1 expression)+(Coef PKHD1L1 ×PKHD1L1 expression)+(Coef DZIP1 ×DZIP1 expression);

[0070] (b) Determine the threshold (cut-off value);

[0071] (c) Compare the result of (a) with the threshold of (b) to obtain the detection result.

[0072] In one or more embodiments, in (c), if the score value is ≥ the threshold, the evaluation is: poor prognosis, high risk of recurrence, or insensitive to immune checkpoint inhibitor treatment; if the score value is < the threshold, the evaluation is: good prognosis, low risk of recurrence, or sensitive to immune checkpoint inhibitor treatment; preferably, the threshold of the risk score 1 is 0.093; the threshold of the risk score 2 is 0; the threshold of the risk score 3 is 0.

[0073] In one or more embodiments, the method for prognosing melanoma or immunotherapy suitability includes: an auxiliary disease analysis method, which is not intended to directly obtain a diagnosis result of the disease but only provides auxiliary analysis / evaluation / scoring.

[0074] Other aspects of the present invention will be apparent to those skilled in the art in view of the disclosure herein. BRIEF DESCRIPTION OF THE DRAWINGS

[0075] Figure 1 , LASSO regression analysis chart.

[0076] Figure 2 , model genes TMEM67, TMEM107, SLC9A3R1, PKHD1L1, DZIP1 and their risk coefficients (Coef).

[0077] Figure 3 , Kaplan-Meier survival analysis diagram of patients in different risk groups in the training set.

[0078] Figure 4 , time-dependent ROC analysis of patients with different risk scores in the training set (left) and response frequency to immunotherapy (right); where AUC represents the area under the curve, and the numbers 1, 2, and 4 represent the ROC curves of subjects who received immunotherapy for 1, 2, and 4 years, respectively.

[0079] Figure 5, Kaplan-Meier survival analysis diagram of patients in different risk groups in the test set.

[0080] Figure 6 , time-dependent ROC analysis of patients with different risk scores in the test set (left) and response frequency to immunotherapy (right); where AUC represents the area under the curve, and the numbers 1, 2, and 4 represent the ROC curves of subjects who received immunotherapy for 1, 2, and 4 years, respectively.

[0081] Figure 7 , 5 Correlation between the gene model and individual characteristics (mutation subtype, pathological stage M, mutation load, neoantigen load, and neopeptide load) in samples before Bms038 treatment.

[0082] Figure 8 , 5 Correlation between the gene model and individual characteristics (mutation subtype, pathological stage M, mutation load, neoantigen load, and neopeptide load) in samples after Bms038 treatment.

[0083] Fig. 9 , 5 Correlation of gene models with individual characteristics (disease stage, sex, Braf mutation, NF1 mutation, NRAS mutation, responsiveness, purity, ploidy) in the Hugo16 dataset.

[0084] Fig.10 , 5 Correlation between the gene model and individual characteristics (disease stage, gender, before Braf mutation, after Braf mutation, synonymous mutation, non-synonymous mutation, indel, SNPs, mutation) in the Van dataset. Mutation is the sum of synonymous mutation and non-synonymous mutation.

[0085] Fig.11 , 5 Gene model in the pre-treatment samples of the Bms038 dataset (Bms038_Pre, Fig.11 AB) and treated samples (Bms038_On, Fig.11 CD) in the verification results.

[0086] Fig.12 Verification results of AB and 5-gene models in Hugo16 dataset.

[0087] Fig.13 Verification results of AB and 5-gene models in the Van dataset.

[0088] Fig.14 Verification results of AB and 5-gene models in the Puch dataset.

[0089] Fig.15 , immune characteristics of different populations in the training set; dark colors represent low-risk groups, and light colors represent high-risk groups.

[0090] Fig.16 , immune characteristics of different populations in the test set; dark colors represent low-risk groups, and light colors represent high-risk groups.

[0091] Fig.17 , immune characteristics of different populations in the Bms038 dataset; dark colors represent low-risk population groups, and light colors represent high-risk population groups.

[0092] Fig.18 , immune characteristics of different populations in the Hugo dataset; dark colors represent low-risk groups, and light colors represent high-risk groups.

[0093] Fig.19 , Immune characteristics of different populations in the Puch dataset; dark colors represent low-risk groups, and light colors represent high-risk groups.

[0094] Fig. 20 , 5 Validation results of the genetic model in tumor tissue samples from 82 patients diagnosed with melanoma in an outpatient setting.

[0095] Fig.21 Validation results of the AB and 4-gene models in the Bms038 dataset (pre-treatment samples).

[0096] Fig. 22 Validation results of the AB and 4-gene models in the Bms038 dataset (post-treatment samples).

[0097] Fig.23 Verification results of the AB and 4-gene models in the Hugo16 dataset.

[0098] Fig.24 Verification results of the AB and 4-gene models in the Puch dataset.

[0099] Fig.25 Verification results of the AB and 4-gene models in the van dataset.

[0100] Fig.26 Validation results of the AB, 4-gene model in tumor tissue samples from 82 patients diagnosed with melanoma in the outpatient clinic.

[0101] Fig. 27 , 3 Validation results of the gene model in the Bms038 dataset (pre-treatment samples).

[0102] Fig.28, 3 Validation results of the gene model in the Bms038 dataset (post-treatment samples).

[0103] Fig.29 , 3 Verification results of the gene model in the Hugo16 dataset.

[0104] Fig.30 , 3 Verification results of the gene model in the Puch dataset.

[0105] Fig.31 , 3 Verification results of the gene model in the van dataset.

[0106] Fig.32 , 3 Validation results of the genetic model in tumor tissue samples from 82 patients diagnosed with melanoma in an outpatient setting. DETAILED DESCRIPTION

[0107] In view of the lack of melanoma prognosis in the prior art, especially the lack of biomarkers for melanoma associated with cilia, the inventors have conducted in-depth research and provided a biomarker related to melanoma prognosis and its application. The biomarkers include TMEM67, TMEM107, SLC9A3R1, PKHD1L1, and DZIP1, which can be used for the diagnosis and / or prediction of melanoma prognosis risk. The present invention also provides a kit suitable for the diagnosis and / or prediction of melanoma prognosis. The present invention provides a new solution for the diagnosis and treatment of melanoma (especially melanoma associated with cilia) in clinical practice.

[0108] the term

[0109] As used in the present invention, "molecular marker (marker)" refers to a biological molecule or a biological molecule fragment, whose change and / or detection can be associated with a specific physical condition or state. The terms "marker (marker)", "molecular marker (marker)" or "biomarker (marker)" can be used interchangeably throughout the disclosure of the invention. In the present invention, unless otherwise stated, the "molecular marker" refers to a "cancer (tumor) marker". In the present invention, unless otherwise stated, the cancer is melanoma. In some specific embodiments, the "melanoma-related gene" refers to a gene related to the growth of cilia and / or the structure of cilia.

[0110] As used in the present invention, the "detection" includes "assessment", "determination", "analysis", "prediction" and "evaluation"; the "evaluation" or "assessment" also includes "scoring".

[0111] As used in the present invention, the "patient", "subject" or "individual" may refer to an organism, and in some aspects, the subject may be a human. The subject providing the sample may include a population at potential risk of a disease or a population diagnosed with a disease. The disease in the present invention refers to melanoma.

[0112] As used in the present invention, the "sample" and "specimen" are used interchangeably, and include substances obtained from an individual or separated tissue, cell or body fluid, which are suitable for tumor marker detection.

[0113] As used in the present invention, the "prognosis" refers to the prediction of the possible consequences of trauma or disease (such as tumors), and the prognostic indicators include short-term efficacy indicators and long-term efficacy indicators, including but not limited to ORR, DCR, OS, and PFS. Among them, "PFS" refers to "Progression Free Survival", which usually refers to the time when the patient's disease does not progress or become resistant after treatment; "OS" refers to "Overall Survival", which refers to the total survival time of all patients in the study. Generally, it is expressed clinically as median OS and median PFS, that is, the survival time / progression-free survival time achieved by 50% of patients.

[0114] As used in the present invention, the "ROC curve" refers to a receiver operating characteristic curve. In certain specific embodiments of the present invention, the ROC curve refers to a ROC curve between a true positive rate and a false positive rate.

[0115] As used in the present invention, the "expression level" may refer to the concentration or amount of the gene / protein of the marker / indicator of the present invention in a sample.

[0116] As used in the present invention, the terms "high expression", "high expression level" and the like are interchangeable and should be used to mean an increase of at least 5%, 10% or 20%, preferably at least 30% or 50%, more preferably at least 80% or 100% or more significantly compared to a "control" or "threshold value". For example, Student's T-test can be repeated for genes with at least one expression intensity exceeding the threshold value to determine significance.

[0117] As used in the present invention, the terms "low expression", "low expression level" and the like are interchangeable and should be used to mean a decrease of at least 5%, 10% or 20%, preferably at least 30% or 50%, more preferably at least 80% or 100% or more significantly compared to a "control" or "threshold value". For example, the Student's T-test can be repeated for genes with at least one expression intensity below the threshold to determine significance.

[0118] As used in the present invention, the setting of a "control" or "threshold" for gene or protein expression is easily set by those skilled in the art based on the subject matter of the present invention. Selecting an appropriate "control" or "threshold" is a routine part of experimental design. For example, the expression level of the corresponding gene / protein can be first analyzed with statistical significance based on samples of subjects (patients) whose prognosis / therapy efficacy is clear, and the expression value obtained is used as the "control" or "threshold".

[0119] As used herein, the "kit" may refer to a system of materials or reagents for implementing the methods disclosed herein.

[0120] As used in the present invention, the definition of cancer staging can be carried out according to existing definition standards in the art.

[0121] As used in the present invention, “ / ” can represent “and” or “or”.

[0122] Biomarkers of the present invention

[0123] In the present invention, by conducting in-depth analysis of samples from clinical patients with melanoma, modules related to the progression of melanoma are identified, and core genes are further screened to obtain: TMEM67, TMEM107, SLC9A3R1, PKHD1L1 and / or DZIP1. The TMEM67, TMEM107 and DZIP1 are closely related to the occurrence and development of melanoma, especially playing an important role in the formation of cilia. The DZIP1 is an important component of the growth and development of some important organs. The SLC9A3R1 encodes a sodium / hydrogen exchange regulatory cofactor, which interacts with a variety of proteins, such as the cystic fibrosis transmembrane conductance regulator and G protein-coupled receptors, and is an important factor in the signal transduction of living organisms. Their combined use as molecular markers is more meaningful for the prognosis assessment of the disease.

[0124] Based on the new discovery of the present invention, a group of markers with diagnostic significance for melanoma is disclosed: TMEM67, TMEM107, SLC9A3R1, PKHD1L1 and / or DZIP1 genes. The present invention also discloses markers, kits and methods for evaluating the prognosis and therapeutic efficacy of melanoma.

[0125] The sequence position of the TMEM67 gene can be referenced to Chromosome 8:93,754,844-93,819,234GRCh38:CM000670.2, and the sequence information can be referenced to https: / / www.ncbi.nlm.nih.gov / gene / 91147#reference-sequences. The present invention may also cover its sequence variants in organisms.

[0126] The sequence position of the TMEM107 gene can be referenced to Chromosome 17:8,172,457-8,176,399GRCh38:CM000679.2, and the sequence information can be referenced to https: / / www.ncbi.nlm.nih.gov / gene / 84314#reference-sequences. The present invention may also cover its sequence variants in organisms.

[0127] The sequence position of the SLC9A3R1 gene can be referenced to Chromosome 17:74,748,628-74,769,353GRCh38:CM000679.2, and the sequence information can be referenced to https: / / www.ncbi.nlm.nih.gov / gene / 9368#reference-sequences. The present invention may also cover its sequence variants in organisms.

[0128] The sequence position of the PKHD1L1 gene can be referenced to Chromosome 8:109,362,461-109,537,207GRCh38:CM000670.2, and the sequence information can be referenced to https: / / www.ncbi.nlm.nih.gov / gene / 93035#reference-sequences. The present invention may also cover its sequence variants in organisms.

[0129] The sequence position of the DZIP1 gene can be referenced to Chromosome 13:95,578,202-95,644,706GRCh38:CM000675.2, and the sequence information can be referenced to https: / / www.ncbi.nlm.nih.gov / gene / 22873#reference-sequences. The present invention can also cover its sequence variants in organisms.

[0130] The molecular markers disclosed in the present invention can be used as markers to evaluate the development of melanoma and the efficacy of treatment. They can be used to understand the disease state of the individual, evaluate or predict the prognosis of the disease risk, and formulate treatment / medication plans.

[0131] As one approach, a method for predicting melanoma using the molecular markers includes: (1) detecting the expression levels of TMEM67, TMEM107, SLC9A3R1, PKHD1L1 and / or DZIP1 in a sample of a melanoma patient; (2) based on the expression levels obtained in (1): when TMEM67, TMEM107, and / or DZIP1 are highly expressed, it indicates that the melanoma patient has a poor prognosis and a short survival period; when SLC9A3R1 and / or PKHD1L1 are highly expressed, it indicates that the melanoma patient has a good prognosis and a long survival period.

[0132] In some embodiments, when detecting, the expression of TMEM67, TMEM107, SLC9A3R1, PKHD1L1 and DZIP1 genes is substituted into the risk score formula to obtain a risk score value (risk value). The risk value is compared with a preset threshold value to obtain the result of the predicted disease prognosis risk. The higher the risk value, the higher the disease prognosis risk. As used in the present invention, when the risk value is higher than the preset threshold value, it indicates that the disease prognosis risk is high and belongs to the high-risk group; when the risk value is lower than the preset threshold value, it indicates that the disease prognosis risk is low and belongs to the low-risk group.

[0133] As used in the present invention, the formula for calculating the "risk score" (RiskScore) is: RiskScore = gene expression 1 × Coef1 + gene expression 2 × Coef2 + ... + gene expression n ×Coef n (Coef: regression coefficient of gene in multivariate Cox regression analysis, n: total number of genes related to prognosis).

[0134] The expression level of the molecular markers of the present invention can be determined according to established standard procedures well known in the art (reference). The determination can be performed at the RNA level, or the cDNA level can be detected after RNA reverse transcription, for example, by real-time fluorescence quantitative PCR technology. At the protein level, for example, by immunohistochemistry technology, ELISA.

[0135] As an optional method, according to the protein of the molecular marker, an antibody that specifically binds to the protein can be used to achieve detection, which can be implemented for clinical samples by immunohistochemical staining. Common immunohistochemical methods include but are not limited to immunofluorescence, immunoenzyme labeling, immunocolloidal gold method, etc. Immunofluorescence method uses the principle of specific binding of antigen and antibody, first labels a known antibody with fluorescein, and uses it as a probe to check the corresponding antigen in the cell or tissue, and observes it under a fluorescence microscope; when the fluorescein in the antigen-antibody complex is irradiated with excitation light, it will emit a certain wavelength of fluorescence, so that the location of a certain antigen in the tissue can be determined, and then quantitative analysis can be performed. In the immunoenzyme labeling method, an enzyme-labeled antibody acts on the tissue or cell, and then the enzyme substrate is added to generate a colored insoluble product or particles with a certain electron density. Through a light microscope or an electron microscope, various antigen components on the cell surface and inside the cell are located and studied. In the immunocolloidal gold method, colloidal gold (gold hydrosol), a special metal particle, is used as a marker. Colloidal gold can rapidly and stably adsorb proteins without significant effects on the biological activity of proteins. Primary antibodies, secondary antibodies or other molecules that can specifically bind to immunoglobulins are labeled with colloidal gold as probes, which can be used to conduct qualitative, positional and quantitative studies on antigens in tissues or cells.

[0136] As an optional method, primers that specifically amplify the molecular markers can be designed according to their sequences for detection. Polymerase chain reaction (PCR) technology is a technology well known to those skilled in the art, and its basic principle is a method for enzymatically synthesizing specific DNA fragments in vitro. The method of the present invention can be carried out using conventional PCR technology. For a molecular marker, the setting of one or more pairs of primers is feasible, and the setting of multiple pairs of primers can obtain multiple groups of amplification products, which may be more conducive to the confirmation of the results.

[0137] As an optional method, according to the sequence of the molecular marker, a suitable probe can be designed and fixed on a microarray or a gene chip. The gene chip generally includes a solid phase carrier and an oligonucleotide probe fixed in order on the solid phase carrier, and the oligonucleotide probe is composed of continuous nucleotides. In order to enhance the strength of the detection signal and improve the accuracy of the detection result, the hybridization-related site is preferably located in the middle of the probe. The solid phase carrier can be made of various commonly used materials in the field of gene chips, such as but not limited to nylon membranes, glass slides or silicon slices modified with active groups (such as aldehyde groups, amino groups, isothiocyanate groups, etc.), unmodified glass slides, plastic sheets, etc. The probe can also contain a segment of amino-modified 1-30 poly-deoxythymidylic acid (poly-dT) at its 5' end. The gene chip contains probes for at least one molecular marker of the present invention; more preferably, the gene chip contains probes for two or more molecular markers; most preferably, one or more gene chips contain probes for all molecular markers of the present invention. For a molecular marker, the setting of one or more probes is feasible, and the setting of multiple probes may be more conducive to the confirmation of the results.

[0138] As an optional method, the primer-probe method can be used, which is more sensitive and quick in qualitative and quantitative detection. For example, the Taqman real-time fluorescence PCR detection technology can be used: during PCR amplification, a specific Taqman probe labeled with fluorescein is added at the same time as a pair of primers. The probe is an oligonucleotide, and its two ends are respectively labeled with a reporter fluorescent group and a quencher fluorescent group. When the probe is intact, the fluorescent signal emitted by the reporter group is absorbed by the quencher group; during PCR amplification, the 5'→3' exonuclease activity of the Taq enzyme will enzymatically degrade the probe, so that the reporter fluorescent group and the quencher fluorescent group are separated, and the fluorescent element is free in the reaction system and emits fluorescence under specific light excitation. As the number of cycles increases, the amplified target gene fragment increases exponentially, and the Ct (cycle threshold, Ct) value is obtained by real-time detection of the corresponding fluorescence signal intensity that changes with amplification. The Ct value, that is, the number of amplification cycles when the fluorescence signal of the amplified product reaches the set threshold during the PCR amplification process, has a linear relationship with the logarithm of the starting copy number of the template. The more template DNA there is, the fewer cycles it takes for the fluorescence to reach the threshold, that is, the smaller the Ct value, thereby achieving quantitative and qualitative analysis of the starting template.

[0139] The method of amplifying a specific gene fragment by PCR is a well-known technique in the art and is not particularly limited in the present invention. The amplified product can be labeled by a method of amplifying with a primer having a labeling group at the 5' end, or by a method of incorporating a mononucleotide with a labeling group during the amplification process, or by a method of adding a detection probe that specifically binds to the amplified product during hybridization. The labeling group includes, but is not limited to, digoxigenin molecule (DIG), biotin molecule (Bio), fluorescein and its derivative biological molecules (FITC, etc.), other fluorescent molecules (such as Cy3, Cy5, etc.), alkaline phosphatase (AP), horseradish peroxidase (HRP), etc.

[0140] The present invention also provides a kit for detection, which may include a system for storing, transporting, or delivering reagents or devices (e.g., primers, probes, etc. in appropriate containers) and / or coordinating materials (e.g., buffers, written instructions for performing an assessment, etc.) from one location to another. For example, the kit may include one or more housings (e.g., boxes) containing the relevant reagents and / or coordinating materials. These contents may be delivered to the intended recipient simultaneously or separately.

[0141] In addition, the kit may also include various reagents required for DNA extraction, PCR, hybridization, color development, etc., including but not limited to: extraction solution, amplification solution, hybridization solution, enzyme, control solution, color development solution, washing solution, antibodies, etc.

[0142] In addition, the kit may also include instructions for use and / or chip image analysis software, etc.

[0143] The present invention also provides a system for evaluating the development and therapeutic efficacy of melanoma, which includes a detection unit and a data analysis unit; the detection unit includes: a detection reagent for determining the expression level of the molecular marker, or a reagent or device of a kit or detection device containing the detection reagent; the data analysis unit includes: a processing unit for analyzing and processing the detection result of the detection unit to obtain the detection or prognosis result of melanoma. The detection reagent includes (but is not limited to): an antibody that specifically binds to the protein encoded by the molecular marker, a primer that specifically amplifies the molecular marker gene, a probe that specifically recognizes the molecular marker gene, etc. The device specifically used for detection may include, but is not limited to: an immunohistochemical device (such as an ELISA detection kit / module / device), a gene sequencing instrument, a chip, a probe group (module), a primer probe group (module) or an electrophoresis device, etc. The detection result includes: a diagnosis result, or a risk assessment / scoring (such as grading) result.

[0144] As an optional method, the data analysis unit that can be used to analyze and process the detection results of the detection unit includes: a calculation or scoring unit; preferably, the unit is provided with a predicted value calculated by a risk scoring formula for TMEM67, TMEM107, SLC9A3R1, PKHD1L1 and DZIP1 genes, which is compared with a preset threshold to obtain the detection result of the prognosis risk of melanoma.

[0145] As an optional method, the system also includes: a unit for detecting individual characteristics; preferably, the characteristics include: mutation subtype, pathological stage M stage, mutation load, neoantigen load, neopolypeptide load, gender, Braf mutation (before Braf mutation, after Braf mutation), NF1 mutation, NRAS mutation, reactivity, purity, ploidy, total number of non-synonymous mutations, synonymous mutations, non-synonymous mutations, insertions and deletions, SNPs, mutations, etc.

[0146] The present invention has the following beneficial effects:

[0147] 1) The present invention uses bioinformatics technology to find markers related to melanoma prognosis for the first time: TMEM67, TMEM107, SLC9A3R1, PKHD1L1, and DZIP1; the expression of these genes can predict the risk of melanoma prognosis;

[0148] 2) The present invention is the first to propose a prognostic model for predicting melanoma patients composed of 5 gene combinations, 4 gene combinations, and 3 gene combinations as molecular markers.

[0149] The present invention is further described below in conjunction with specific examples. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods in the following examples where specific conditions are not specified are usually carried out according to conventional conditions such as those described in J. Sambrook et al., Molecular Cloning Experiment Guide, 3rd Edition, Science Press, or according to the conditions recommended by the manufacturer.

[0150] Experimental methods

[0151] 1. Data collection and organization

[0152] Through literature search, the inventors collected a total of 6 sets of RNA high-throughput sequencing (RNA-seq) and partial exome sequencing (WES) data for patients receiving anti-PD-1 antibody or anti-CTLA-4 antibody immunotherapy. Among them, 121 samples in the Liu19 dataset and 91 samples in gide19 were combined to form a total of 212 samples. 152 samples were randomly selected from these 212 samples as training sets, and the remaining 60 were used as test sets. The other 4 sets of data were used as independent validation sets (Table 1).

[0153] Table 1. Dataset of the present invention

[0154]

[0155]

[0156] 2. Gene set enrichment analysis

[0157] In the tumor microenvironment, tumor tissue is infiltrated by various cells, and immune cells infiltrating the tumor can profoundly affect the progression of the tumor. In order to accurately evaluate the composition of immune cells in the tumor microenvironment, the inventors can quantify tumor-infiltrating immune cells from RNA sequencing data in many ways. Gene set enrichment (GSVA) ​​analysis is a recognized method, and the main idea is to condense the information in the gene expression profile into a pathway or feature. Compared with single gene analysis, the advantages of this method include noise reduction and dimensionality reduction, as well as higher biological interpretation capabilities. The inventors used two gene sets, 29_Immu (from: DOI: 10.1016 / j.ccell.2021.04.014) and danaher (from: DOI: 10.1186 / s40425-017-0215-8) as the background, combined with the R package (R language toolkit) GSVA to convert the gene expression profile into the enrichment score of the sample in each immune feature.

[0158] 3. LASSO regression

[0159] LASSO regression is an example of regularization of a regression algorithm. Regularization is a method that solves the overfitting problem by adding additional parameters, thereby reducing the parameters of the model and limiting the complexity. LASSO regression is an L1 penalty model. The inventor only needs to add the L1 norm to the cost function of the least squares, increase the value of the hyperparameter α, strengthen the regularization strength of the model, and reduce the weight of the model. By adjusting the strength of the regularization, some weights can be turned to zero, which makes the LASSO method a very powerful dimensionality reduction technique. The present invention uses the R package glmnet to optimize features and construct the corresponding COX proportional hazard model.

[0160] 4. Survival analysis

[0161] Survival analysis is a statistical analysis method that studies the distribution of survival time and the relationship between survival time and related factors. Survival analysis involves time-sensitive indicators such as the healing, death, or growth and development of related diseases. The Kaplan-Meier survival curve estimates the survival rate and median survival time according to the distribution of survival time, and displays it in the form of a survival curve to analyze the survival characteristics. The Log-rank test compares the survival curves between two or more groups, generally the survival rate and its standard error, to study the differences between the groups. The COX hazard ratio model is used to analyze the effects of two or more variables on survival. In the present invention, the Kaplan-Meier (KM) method is used to estimate the survival rate, make a survival curve, and then analyze whether there are significant differences in the survival curves between multiple groups according to the Log-rank test. Finally, the COX hazard ratio model is used to study the effect of a certain factor on survival. All of the above methods are based on the R packages survminer and survival.

[0162] 5. Software Package

[0163] The glmnet software package, survminer software package, survival software package, GSVA software package, tidyverse software package, timeROC software package, ggplot2 software package, caret software package, stats software package, MCPcounter software package, clusterProfiler software package, limma software package, and enrichplot software package involved in the following embodiments are all prior art, derived from https: / / cran.r-project.org or http: / / www.bioconductor.org / , and run in R software after loading.

[0164] Example 1: Screening of candidate cilia features

[0165] The inventors screened 112 cilia-related pathways from the GO database (http: / / geneontology.org / ) as background pathways, and then performed GSVA analysis on 121 samples of liu19, converting the gene expression profiles into ES scores between samples and immune features. Based on ES analysis, survival analysis was performed and 10 cilia pathways related to prognosis (PFS and OS) were screened. Finally, 13 prognosis (PFS and OS)-related features were screened from 161 genes in these 10 pathways as selected cilia features (Table 2).

[0166] Table 2. 13 selected ciliary features

[0167]

[0168] Example 2: LASSO risk model construction

[0169] The aforementioned 152 samples were used as training sets. In the training sets, LASSO (the Least Absolute Shrinkage and Selection Operator) regression was used to screen the optimal gene set ( Figure 1 ). Among the 13 candidate cilia features, 9 optimal gene sets (CDH23, CEP290, DZIP1, PCDHB15, PKHD1L1, RIPOR2, SLC9A3R1, TMEM107, TMEM67) were obtained. The risk prognosis model was constructed by combining these 9 genes with COX regression. Using stepwise regression, 500 cycles were performed, and finally a risk model consisting of the five genes (TMEM67, TMEM107, SLC9A3R1, PKHD1L1, DZIP1) and their risk coefficients shown in Table 3 was obtained ( Figure 2 ).

[0170] Table 3. Model genes and their risk coefficients

[0171]

[0172]

[0173] According to the COX regression coefficient and the optimized 5 genes, the risk score formula is obtained:

[0174] Risk score = (0.01 × TMEM67) + (0.031 × TMEM107) + (-0.024 × SLC9A3R1) + (-0.172 × PKHD1L1) + (0.012 × DZIP1).

[0175] The threshold was determined according to the surv_cutpoint in the R language toolkit (according to the operation logic of the surv_cutpoint function in the R package, the maximum selection rank statistical method was used to calculate the best cut-off point with survival data as the threshold, and the final threshold was determined to be 0.093). The patients in the training set were divided into a high-risk group (≥0.093, evaluated as poor prognosis, high risk of recurrence and insensitive to immunotherapy) and a low-risk group (<0.093, evaluated as good prognosis, low risk of recurrence and sensitive to immunotherapy). Kaplan-Meier survival analysis showed that the prognosis of patients in the high-risk group was worse than that in the low-risk group ( Figure 3 ), the difference is extremely significant, p<0.0001.

[0176] For patients with different risk scores in the training set, the time-dependent ROC curves showed that the area under the curve (AUC) values ​​for 1, 2, and 4 years were 0.703, 0.683, and 0.909, respectively ( Figure 4 ), indicating that the risk score can predict patient survival with high accuracy.

[0177] In addition, when analyzing the different immune efficacy in the training set, it was found that the response rate in the low-risk group (responding patients and patients with stable disease) was significantly higher than the non-response rate, which further shows that the model can be used to predict the patient's response to anti-PD-1 / anti-CTLA-4 immunotherapy.

[0178] Similarly, in the test set, it was observed that the prognosis of the low-risk group was significantly better than that of the high-risk group ( Figure 5 ), the difference is extremely significant, p<0.0001.

[0179] For patients with different risk scores in the test set, the time-dependent ROC curves showed that the area under the curve (AUC) values ​​for 1, 2, and 4 years were 0.708, 0.683, and 0.791, respectively ( Figure 6 ).

[0180] In addition, when analyzing the different immune efficacy in the test set, it was found that the non-response rate in the high-risk group was about twice that in the low-risk group (50% vs 24%). This further shows that the model can be used to predict the patient's response to anti-PD-1 / anti-CTLA-4 immunotherapy.

[0181] Example 3. Functions of TMEM67, TMEM107, SLC9A3R1, PKHD1L1, and DZIP1 genes

[0182] The five genes in the model are all related to the composition of cilia and their signal transmission, as shown in Table 4. Among them, TMEM67, TMEM107 and DZIP1 play an important role in the formation of cilia, and DZIP1 is also an important component of the growth and development of some important organs. SLC9A3R1 encodes a sodium / hydrogen exchange regulatory cofactor, which interacts with a variety of proteins, such as the cystic fibrosis transmembrane conductance regulator and G protein-coupled receptors, and is an important factor in the signal transduction of living organisms.

[0183] Table 4. Gene functional information

[0184]

[0185] Example 4: Independence of the model

[0186] To verify the independence of the model, the inventors analyzed the relationship between the model and individual characteristics such as pathological stage, gender, tumor mutation load, neoantigen load, tumor purity, ploidy, and important melanoma gene mutations (NF1 / KRAS / BRAF).

[0187] The data sets and their information are used are shown in Table 1.

[0188] According to the 5-gene model of Example 2 above, the data were divided into a high-risk group (≥0.093, evaluated as poor prognosis, high risk of recurrence) and a low-risk group (<0.093, evaluated as good prognosis, low risk of recurrence). The correlation of clinical characteristic factors between the high-risk group and the low-risk group was analyzed by chi-square test. Among them, the clinical characteristic factors include pathological stage, gender, tumor mutation load, neoantigen load, tumor purity, ploidy, and important melanoma gene mutations (NF1 / KRAS / BRAF).

[0189] The results showed that in the Bms038 pre-treatment sample dataset ( Figure 7 )、Bms038 post-treatment sample dataset ( Figure 8 )、Hugo16 dataset( Fig. 9 )、Van dataset( Fig.10 ), none of the individual characteristics were significantly correlated with the model.

[0190] The results showed that the 5-gene model is independent and not affected by the above factors. It can be used independently to prognose or predict low-risk populations that are effective for immunotherapy (immune checkpoint inhibitors, specifically including anti-PD-1 antibodies / anti-CTLA-4 antibody immunotherapy).

[0191] Example 5.5 Robustness of the genetic model and applicability for immunotherapy

[0192] The independent validation set data in the data set of Table 1 was used as the validation sample, and the above risk score formula was used for analysis to verify the robustness of the model and the applicability of immunotherapy (anti-PD-1 / anti-CTLA-4 immunotherapy):

[0193] Risk score = (0.01 × TMEM67) + (0.031 × TMEM107) + (-0.024 × SLC9A3R1) + (-0.172 × PKHD1L1) + (0.012 × DZIP1);

[0194] Among them, if the score value is ≥0.093, it is evaluated as poor prognosis and high risk of recurrence; if the score value is <0.093, it is evaluated as good prognosis and low risk of recurrence. Kaplan-Meier survival analysis (Log-Rank) and Fisher's exact test (Fisher test) were performed in combination with the risk score results to evaluate the immunotherapy applicability of the model.

[0195] The inventors verified the 51 pre-treatment samples (Bms038_Pre) and 50 post-treatment samples (Bms038_On) in the Bms038 data set and found that the prognosis and response rate of the low-risk group screened by the model were significantly higher than those of the high-risk group ( Fig.11 , before treatment: Log_rank p=0.031, Fisher test p=0.143, after treatment: Log_rank p<0.001, Fisher test p=0.02). In addition, in the Hugo16 dataset ( Fig.12 , Log_rank p=0.004, Fisher test p=0.033), Van dataset ( Fig.13 , Log_rank p=0.017, Fisher test p=0.408) and Puch dataset ( Fig.14 Similar results were observed in the 96 samples (P = 0.05, Log_rank p = 0.038, Fisher test p = 0.087).

[0196] Furthermore, the sensitivity and specificity of the 5-gene model of the present invention in multiple data sets were analyzed with a positive response to immunotherapy, and the results are shown in Tables 5 and 6. The results show that the model of the present invention exhibits good specificity and sensitivity in multiple data sets.

[0197] Table 5. Sensitivity of the 5 gene models of the present invention

[0198]

[0199] Table 6. Specificity of the 5 gene models of the present invention

[0200]

[0201] These results all indicate that the model is highly robust and applicable to immunotherapy. In multiple sets of melanoma-related data, it can be seen that the model can screen out low-risk populations with significantly better prognosis, and thus it will also be robust after actual disease prognosis analysis.

[0202] Example 6: Immune signature analysis of data

[0203] Bioinformatics analysis of immune features of the dataset in Table 1 showed that the low-risk group was mainly enriched in immune activation-related pathways, showing an immune activation state; while the high-risk group was mainly enriched in immunosuppression-related pathways such as EMT, showing an immune suppression state (such as Fig.15 , Fig.16 , Fig.17 , Fig.18 , Fig.19 ).

[0204] The results of bioinformatics analysis once again confirmed the applicability of the 5-gene model for immunotherapy.

[0205] Example 7. Clinical application of markers

[0206] With informed consent, tumor tissue samples were collected from 82 patients diagnosed with melanoma in the clinic. The same 5-gene model and analysis method as in Example 2 were used to score these patient samples.

[0207] Table 7. Prediction of the 5-gene model of the present invention in clinical patients

[0208]

[0209] The results predicted by the model of the present invention are shown in Table 7. Among the 82 subjects, 42 test results were higher than the threshold, and it is expected that this group of patients are high-risk patients, and are also a group that does not respond to immunotherapy. The test results of 40 subjects were lower than the threshold, and it is expected that this group of patients are low-risk patients, and are also a group that is effective for immunotherapy.

[0210] Therefore, based on the prediction results, the prognosis and response rate of patients in the high-risk group and low-risk group after anti-PD-L1 monoclonal antibody treatment were evaluated. The results showed that the overall survival of patients in the low-risk group after anti-PD-L1 monoclonal antibody treatment was significantly higher than that in the high-risk group ( Fig. 20 ), and the response rate in the low-risk group was significantly higher than that in the high-risk group ( Fig. 20 ). This shows that the prediction results of the model of the present invention are accurate.

[0211] Example 8: Prediction models and prediction results of different gene combinations

[0212] Next, the inventors explored whether reducing the number of genes could establish a prediction model that can predict the results as accurately as the model in Example 2. A 4-gene prediction model and a 3-gene prediction model as shown in Table 8 were constructed, and the data set in Table 1 was used in combination with the risk score results to perform Kaplan-Meier survival analysis and Fisher's exact test to explore the prediction accuracy of the model.

[0213] Table 8. Prediction models of different gene combinations

[0214]

[0215]

[0216] The prediction results of the 4-gene model showed that the prognosis of the low-risk group was significantly better than that of the high-risk group, whether in the various data sets in Table 1 or in the 82 clinical samples ( Fig.21 A p=0.041, Fig. 22 Ap=0.0066、 Fig.23 Ap=0.027, Fig.24 A p=0.031, Fig.25 A p=0.038, Fig.26 A p<0.0001). In addition, the response rate of low-risk people to anti-PD-1 / CTLA-4 immunotherapy was significantly higher than that of the high-risk group. The proportion of disease progression in the high-risk group was approximately twice that of the low-risk group ( Fig.21 B. Fig. 22 B. Fig.23 B. Fig.24 B. Fig.25 B. Fig.26 B).

[0217] The prediction results of the 3-gene model showed that the prognosis of the low-risk group was significantly better than that of the high-risk group, whether in each data set in Table 1 or in the 82 clinical samples ( Fig. 27 A p=0.0015, Fig.28 Ap=0.00033、 Fig.29 A p=0.0076, Fig.30 A p=0.0029, Fig.31 A p=0.0048, Fig.32 A p=0.0017). In addition, the response rate of low-risk people to anti-PD-1 / CTLA-4 immunotherapy was significantly higher than that of the high-risk group. The proportion of disease progression in the high-risk group was approximately twice that of the low-risk group ( Fig. 27 B. Fig.28 B. Fig.29 B. Fig.30 B. Fig.31 B. Fig.32 B).

[0218] The above results show that the 4-gene combination (DZIP1, SLC9A3R1, TMEM107, TMEM67) and 3-gene combination (DZIP1, PKHD1L1, SLC9A3R1) are significant and can be used as biomarkers related to melanoma prognosis and immunotherapy.

[0219] The above-mentioned embodiments only express several implementation methods of the present invention, and the description thereof is relatively specific and detailed, but it cannot be understood as limiting the scope of the patent of the present invention. It should be pointed out that, for a person of ordinary skill in the art, several variations and improvements can be made without departing from the concept of the present invention, and these all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be subject to the attached claims. At the same time, all the documents mentioned in the present invention are cited as references in this application, just as each document is cited as reference separately.

Claims

1. Use of molecular markers in the preparation of a detection system for the prognosis of melanoma; the molecular markers are composed of TMEM67, TMEM107, SLC9A3R1, PKHD1L1 and DZIP1, or are composed of TMEM67, TMEM107, SLC9A3R1 and DZIP1, or are composed of SLC9A3R1, PKHD1L1 and DZIP1; the detection system comprises: A detection reagent, a kit or a detection device.

2. The use according to claim 1, characterized in that The prognosis includes the prognosis of suitability for immunotherapy, the immunotherapy is immune checkpoint inhibitor therapy, and the immune checkpoint inhibitor therapy is anti-PD-1 / anti-CTLA-4 immunotherapy.

3. The use according to claim 1, characterized in that The prognosis includes: Based on the expression of molecular markers: (a) To analyze the sensitivity of melanoma patients to immunotherapy; (b) analysis of major pathological response and / or survival in patients with melanoma; or (c) performing a risk analysis or score for the development of melanoma in patients with melanoma.

4. The use according to claim 3, characterized in that The analysis of melanoma patients' sensitivity to immunotherapy also includes: formulating a treatment / medication plan.

5. The use according to any one of claims 1 to 4, characterized in that: The detection reagents include: PCR detection reagents and sequencing reagents.

6. The use according to claim 5, characterized in that The detection reagent comprises: a primer for specifically amplifying the molecular marker gene and a probe for specifically identifying the molecular marker gene.

7. The use according to claim 1, characterized in that The kit includes the detection reagent.

8. The use according to claim 7, characterized in that The detection device includes: a gene sequencing instrument, a chip, a probe set, a primer probe set or an electrophoresis device.

9. The use according to claim 1, characterized in that Analytical methods include: (a) For the sample to be tested, the expression of TMEM67, TMEM107, SLC9A3R1, PKHD1L1 and / or DZIP1 is measured, and risk analysis or scoring is performed using any of the following risk scoring formulas: Risk score 1 = (Coef TMEM67 ×TMEM67 expression) + (Coef TMEM107 ×TMEM107 expression) +(Coef SLC9A3R1 ×SLC9A3R1 expression) +(Coef PKHD1L1 ×PKHD1L1 expression) + (Coef DZIP1 ×DZIP1 expression); Risk score 2 = (Coef TMEM67 ×TMEM67 expression) + (Coef TMEM107 ×TMEM107 expression) +(Coef SLC9A3R1 ×SLC9A3R1 expression) + (Coef DZIP1 ×DZIP1 expression); Risk score 3 = (Coef SLC9A3R1 ×SLC9A3R1 expression) +(Coef PKHD1L1 ×PKHD1L1 expression) +(Coef DZIP1 ×DZIP1 expression); (b) Determine the threshold (cut-off value); (c) Compare the result of (a) with the threshold of (b) to obtain the detection result.

10. The use according to claim 9, characterized in that (a), the Coef TMEM67 is 0 to 1; the Coef TMEM107 is 0 to 1; the Coef SLC9A3R1 is -1 to 0; the Coef PKHD1L1 is -1 to 0; the Coef DZIP1 It is 0 to 1.

11. The use according to claim 10, characterized in that (a), the Coef TMEM67 is 0.01±0.005; the Coef TMEM107 is 0.031±0.015; the Coef SLC9A3R1 is -0.024±0.01; the Coef PKHD1L1 is -0.172±0.07; the Coef DZIP1 It is 0.012±0.

008.

12. The use according to claim 11, characterized in that (a), the Coef TMEM67 is 0.01±0.002; the Coef TMEM107 is 0.031±0.01; the Coef SLC9A3R1 is -0.024±0.005; the Coef PKHD1L1 is -0.172±0.03; the Coef DZIP1 It is -0.024±0.

004.

13. The use according to claim 9, characterized in that In (c), if the score value is ≥ the threshold, the patient is evaluated as having a poor prognosis, a high risk of recurrence, or being insensitive to immune checkpoint inhibitor treatment; if the score value is < the threshold, the patient is evaluated as having a good prognosis, a low risk of recurrence, or being sensitive to immune checkpoint inhibitor treatment.

14. A system for melanoma prognosis, comprising a detection unit and a data analysis unit; The detection unit comprises: A detection reagent for determining the expression level of a molecular marker, or a kit or detection device containing the detection reagent; The molecular markers consist of TMEM67, TMEM107, SLC9A3R1, PKHD1L1 and DZIP1, or consist of TMEM67, TMEM107, SLC9A3R1 and DZIP1, or consist of SLC9A3R1, PKHD1L1 and DZIP1; The data analysis unit includes: a processing unit for analyzing and processing the detection result of the detection unit to obtain a melanoma prognosis result; the analysis of the data analysis unit includes: (a) For the sample to be tested, the expression of TMEM67, TMEM107, SLC9A3R1, PKHD1L1 and / or DZIP1 is measured, and risk analysis or scoring is performed using any of the following risk scoring formulas: Risk score 1 = (Coef TMEM67 ×TMEM67 expression) + (Coef TMEM107 ×TMEM107 expression) +(Coef SLC9A3R1 ×SLC9A3R1 expression) +(Coef PKHD1L1 ×PKHD1L1 expression) + (Coef DZIP1 ×DZIP1 expression); Risk score 2 = (Coef TMEM67 ×TMEM67 expression) + (Coef TMEM107 ×TMEM107 expression) +(Coef SLC9A3R1 ×SLC9A3R1 expression) + (Coef DZIP1 ×DZIP1 expression); Risk score 3 = (Coef SLC9A3R1 ×SLC9A3R1 expression) +(Coef PKHD1L1 ×PKHD1L1 expression) +(Coef DZIP1 ×DZIP1 expression); (b) Determine the threshold (cut-off value); (c) Compare the result of (a) with the threshold of (b) to obtain the detection result; (a), the Coef TMEM67 is 0 to 1; the Coef TMEM107 is 0 to 1; the Coef SLC9A3R1 is -1 to 0; the Coef PKHD1L1 is -1 to 0; the Coef DZIP1 It is 0 to 1.

15. The system for melanoma prognosis according to claim 14, characterized in that: The prognosis includes the prognosis of suitability for immunotherapy, the immunotherapy is immune checkpoint inhibitor therapy, and the immune checkpoint inhibitor therapy is anti-PD-1 / anti-CTLA-4 immunotherapy.

16. The system for melanoma prognosis according to claim 14, wherein: In (c), if the score value is ≥ the threshold, the patient is evaluated as having a poor prognosis, a high risk of recurrence, or being insensitive to immune checkpoint inhibitor treatment; if the score value is < the threshold, the patient is evaluated as having a good prognosis, a low risk of recurrence, or being sensitive to immune checkpoint inhibitor treatment.